Skip to main content
. Author manuscript; available in PMC: 2013 May 21.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2009 Jan 23;75(1):156–163. doi: 10.1016/j.ijrobp.2008.10.043

Table 3.

Bolus wash-in slopes, ratios of Ktrans, fBV, and rCBV before and after one cycle of bevacizumab (n= 10 patients).

Perfusion MRI parameter Baseline After 1 cycle of bevacizumab P
Bolus wash-in slopes 1.79±1.82 0.58±0.37 0.02
Ktrans* 1.79±0.78 1.24±0.21 0.03
fBV 1.83±0.80 1.34±0.68 0.01
rCBV†† 1.93±0.93 1.23±0.28 0.02

All measurements are shown as mean ± standard deviation.

*

Ktrans=transfer coefficient, a marker of microvascular permeability;

fBV=fractional blood volume;

††

rCBV=relative cerebral blood volume.

HHS Vulnerability Disclosure